Watson announces launch of Generess Fe, patient support program

PARSIPPANY, N.J. — Watson Pharmaceuticals has launched a low-dose chewable contraceptive, the company said Monday.

Watson announced the U.S. commercial launch of Generess Fe (norethindrone and ethinyl estradiol chewable tablets, and ferrous fumarate chewable tablets) in the 0.8-mg/25-mcg strength.

As part of the launch, Watson has created the “I am Generess” patient support program, which caps participant cost for the drug at $25 per prescription and donates $5 in the person’s name to one or more women’s charities of the patient’s choosing, including the National Coalition Against Domestic Violence; the Rape, Abuse and Incest National Network; and the Society for Women’s Health Research.